ANU Stock Chart & Stats
€0.40
-€0.05(-3.54%)
At close: 4:00 PM EST
€0.40
-€0.05(-3.54%)
Day’s Range― - ―
52-Week Range€1.10 - €4.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)213.00
Market Cap
€3.18M
Enterprise Value€3.22
Total Cash (Recent Filing)€250.45K
Total Debt (Recent Filing)€15.07K
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,730,565
10 Day Avg. Volume640
30 Day Avg. Volume213
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)€2.02M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low reported debt reduces solvency and interest-rate risk, giving management financial flexibility to prioritize R&D and clinical programs. Over a multi-month horizon this lowers the chance of distress financing and supports execution of trials without heavy interest burdens.
Meaningful Narrowing Of LossesA large reduction in operating losses signals improved cost discipline or more focused program spend, which sustainably reduces future cash needs if maintained. This structural improvement increases probability of reaching clinical milestones with lower incremental funding.
Focused Clinical-stage PipelineA concentrated, disease-focused pipeline builds domain expertise and a clearer regulatory and development path. Over months, this specialization can attract strategic partnerships, targeted investors, or licensing opportunities that de-risk commercialization compared with unfocused R&D.
Bears Say
No RevenueAbsence of product revenue means operations are not self-sustaining and the company depends on external financing to fund trials. Over 2–6 months this elevates execution risk, increases potential for dilution, and ties progress to capital markets or partner deals rather than internal cash generation.
Persistent Cash BurnSustained negative operating and free cash flow demonstrates ongoing cash outflows that outpace internal generation. This structural burn requires repeated financing rounds or partnerships, compressing runway and forcing potential trade-offs in program prioritization and timelines.
Shrinking Equity BaseMaterial reduction in equity over time weakens the capital cushion available to absorb clinical setbacks or fund pivotal studies. Structurally this raises the likelihood of dilutive financings, reduces negotiating leverage with partners, and constrains long-term strategy execution.
XORTX Therapeutics Inc News
ANU FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was €1.09 and its highest was €4.10 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is €3.18M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 18 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -€0.509 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,730,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -€0.509 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:ANU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.